About Event

An Antibody binding and developability are key determinants for successful antibody drug design. I will show recent work on how sequence, structure, and molecular dynamics approaches can be combined to understand the plasticity of antibody properties. In light of these results, I will comment on current standardization efforts by the AIRR Community and how these efforts may fuel large-scale data analyses in industry and academia.

‍